Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Study Type: Treatment
Phase: III
NCTID: NCT02521493
Principal Investigator:
Keith August
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
A Phase IIA, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 a Liposomal Grb2 Antisense Oligonucleotide in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia AML Who Are Ineligible for Intensive Induction Therapy
A Phase I Study of DS-3032B in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia That are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination with Standard Chemotherapy for the Treatment of Newly-Diagnosed Acute Myeloid Leukemia
A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
Study Type: Treatment
Phase: I
NCTID: NCT06146257
Principal Investigator:
Jesus Gonzalez Lugo
A Phase I Study of Allogeneic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products MT-401-OTS Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes RAPID
Study Type: Treatment
Phase: I
NCTID: NCT06552416
Principal Investigator:
Haitham Abdelhakim